The China market for early-screening cancer products has grown rapidly in recent years, fueled by the country’s huge cancer caseload and a growing middle class that can afford such services. One major beneficiary of that boom is New Horizon Health Ltd. (6606.HK), whose latest results released last week show its revenue more than tripled to 765 million yuan ($110.8 million) last year.
作者莫莉，本文仅代表个人观点。
您已阅读5%（401字），剩余95%（7715字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。